Axsome Therapeutics (AXSM)

by **investar** » Fri Jun 02, 2017 5:16 am

This stock popped up on my screen after the news about one of its pipeline drugs, AXS-05, got FDA fasttrack designation for treatment of agitation in patients with Alzheimer's:

http://phx.corporate-ir.net/phoenix.zht ... ID=2270682

IPO was in Nov 2015 at 8$, top jan 16 15$, now for sale at 4$, low is 3.5$.

4 Phase 3 trials with two drug candidates.
Enough cash to fund these trials, first results expected 3Q 17.

corporate presentation:

http://phx.corporate-ir.net/phoenix.zht ... sentations

by **helios** » Fri Jun 02, 2017 9:16 am

Hi Investar,

Seems you are right.

Looks interesting to me as well. There is a technical gap to be filled, alongside with the fast track approval.

Let's meet and discuss.

by **helios** » Sat Jun 03, 2017 7:20 am

https://www.google.com.sg/amp/s/seeking ... -catalysts

Read the analyst report which was very well done up. I don't believe in their oral dose of 02 candidate for knee OA. But their 05 candidate antidepressant (known mechanism of action) seems compelling. Will monitor closely. The price I wanna is less than @ 3.5 as this stock has slower momentum if you observed the trade volumes. However, the liquidity volume is turning up lately.

by **helios** » Sat Jun 03, 2017 9:15 am

If we trade on candidate 05 positive, then prelim data will be out Q1 2018. Can wait if can collect it @ 3.

by **investar** » Sat Jun 03, 2017 10:26 pm

Candidate 05: maybe indeed more interesting; we will find out more about it in early 2018.

In Q3 and Q4 of 2017, there will be Phase 3 results on the candidate 02, and these will decide wether anyone will be able to pick up shares at 3$ or even below that. I already took a small speculative long position.

https://www.clinicaltrials.gov/show/NCT02504008

by **helios** » Sun Jun 04, 2017 8:54 am

Hi Investar,

You are very smart to point me to NIH CT webbie.

I am sure they will definitely hit the endpoints (all these are questionnaires assessments types, and easier to do gamification than drug baseline biomarkers)

Trial closure is June 2017, given a three to six months for statistics analysis, yes we might see some action late 2017. If not wrong, all the bone conference AO Annual Meetings are held in March. Again, no hurry. Wait for the right price to cherry pick ...

by **investar** » Thu Jun 29, 2017 3:00 am

Good addition to the board of directors; it certainly adds credibility and thus the investment community seems to like it.
http://phx.corporate-ir.net/phoenix.zht ... ID=2281540

Stock now 5.7$ - solid volume

by **investar** » Fri Jul 28, 2017 2:44 am

Above 6$, after Ladenburg Thalmann puts a price target of 31$

New candidate 06 passed Phase1

by **investar** » Tue Jan 08, 2019 4:13 am

Big day for this one today, +200% to 8.5$
Lots of news in the pipeline in the next few months.
Could go above 12$ by the end of Q1

by **investar** » Sat Mar 02, 2019 2:16 am

It hit 10.8$ last month, now back to 7.8$, some say this will jump as high as 20$ if results of two more expected trials are good (Q1 2019).

Support Our Forum
Donations Collected by OMICSBIO
on behalf of InvestIdeas.net